The researchers note that there is no data on Xarelto in human pregnancy and recommend that additional safety studies be conducted before administering the drug to pregnant women.
Xarelto has been previously connected to serious health issues such as gastrointestinal bleeding, brain hemorrhaging, blood clots, and stroke and the researchers advise pregnant patients to use it with caution. Currently, over 500 cases are pending in state and federal courts across the United States. In these cases, plaintiffs have alleged in part that the defendants responsible for developing and marketing Xarelto, Bayer Healthcare, janssen Pharmaceuticals, and Johnson & Johnson, failed to warn doctors and patients that patients on Xarelto would need medical monitoring and that they were at an increased risk for certain types of bleeding events. Further, plaintiffs claim the manufacturers failed to notify patients that there was no reversal agent that could quickly stop the anticoagulant effects of Xarelto, thereby increasing the risk of uncontrolled bleeding in some patients.
Several partners at Seeger Weiss LLP serve as leadership in this multidistrict litigation based in the US District Court for the Eastern District of Louisiana.
Seeger Weiss LLP is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go to www.seegerweiss.com.
